Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Ocular Therapeutix, Inc (OCUL)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 174,000,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Ocular Therapeutix is a biopharmaceutical company. Co. commercializes two products in the U.S.: DEXTENZA®, an intracanalicular insert for the treatment of both post-surgical ocular inflammation and pain and ocular itching associated with allergic conjunctivitis, and ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. Co. also has product candidates in preclinical and clinical development designed to utilize its bioresorbable hydrogel technology to treat retinal diseases including wet age-related macular degeneration; glaucoma and ocular hypertension; and ocular surface diseases and conditions including dry eye disease.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 10,000 940,851
Total Buy Value $0 $0 $69,600 $7,069,600
Total People Bought 0 0 1 2
Total Buy Transactions 0 0 1 2
Total Shares Sold 53,749 115,555 205,355 368,958
Total Sell Value $613,453 $1,341,101 $1,999,856 $3,033,385
Total People Sold 5 7 8 12
Total Sell Transactions 5 13 24 42
End Date 2025-10-23 2025-07-22 2025-01-21 2024-01-22

   
Records found: 201
  Page 1 of 9  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Robins Jason Shand Interim CFOOfficer   •       –      –    2026-01-20 3 IO $0.00 $0 D/D 0 52,656     -
   Meyers Steve Lawrence Chief Commercial Officer   •       –      –    2026-01-02 4 A $0.00 $0 D/D 64,900 217,628     -
   Heier Jeffrey S. Chief Scientific Officer   •       –      –    2026-01-02 4 A $0.00 $0 D/D 79,112 326,425     -
   Nayak Sanjay Chief Strategy Officer   •       –      –    2026-01-02 4 A $0.00 $0 D/D 64,900 342,760     -
   Notman Donald See Remarks   •       –      –    2026-01-02 4 A $0.00 $0 D/D 79,112 389,292     -
   Saroj Namrata Chief Business Officer   •       –      –    2026-01-02 4 A $0.00 $0 D/D 79,112 254,620     -
   Waheed Nadia Chief Medical Officer   •       –      –    2026-01-02 4 A $0.00 $0 D/D 79,112 326,280     -
   Kaiser Peter Chief Development Officer   •       –      –    2026-01-02 4 A $0.00 $0 D/D 79,112 271,918     -
   Anderman Todd Chief Legal Officer   •       –      –    2026-01-02 4 A $0.00 $0 D/D 64,900 152,468     -
   Dugel Pravin See Remarks   •       •      –    2025-11-26 4 GA $0.00 $0 I/I 49,754 300,115     -
   Dugel Pravin See Remarks   •       •      –    2025-11-26 4 GD $0.00 $0 I/I 49,754 0     -
   Dugel Pravin See Remarks   •       •      –    2025-11-24 4 S $12.04 $235,141 D/D (19,530) 3,157,960     -
   Heier Jeffrey S. Chief Scientific Officer   •       –      –    2025-11-24 4 S $12.04 $41,767 D/D (3,469) 245,940     -
   Nayak Sanjay Chief Strategy Officer   •       –      –    2025-11-24 4 S $12.04 $22,611 D/D (1,878) 277,860     -
   Kaiser Peter Chief Development Officer   •       –      –    2025-11-24 4 S $12.02 $36,144 D/D (3,007) 191,433     -
   Saroj Namrata Chief Business Officer   •       –      –    2025-11-05 4 S $10.74 $277,790 D/D (25,865) 174,135     -
   Anderman Todd Chief Legal Officer   •       –      –    2025-10-08 4 S $12.34 $137,369 D/D (11,132) 87,568     -
   Heier Jeffrey S. Chief Scientific Officer   •       –      –    2025-10-02 4 S $11.04 $115,942 D/D (10,502) 249,409     -
   Kaiser Peter Chief Development Officer   •       –      –    2025-10-02 4 S $11.03 $106,473 D/D (9,653) 194,440     -
   Dugel Pravin See Remarks   •       •      –    2025-09-09 4 GA $0.00 $0 I/I 49,754 49,754     -
   Dugel Pravin See Remarks   •       •      –    2025-09-09 4 GD $0.00 $0 D/D 49,754 3,177,490     -
   Notman Donald See Remarks   •       –      –    2025-09-02 4 S $12.43 $13,250 D/D (1,066) 308,807     -
   Dugel Pravin See Remarks   •       •      –    2025-08-25 4 S $12.04 $258,788 D/D (21,494) 3,227,244     -
   Heier Jeffrey S. Chief Scientific Officer   •       –      –    2025-08-25 4 S $12.04 $36,879 D/D (3,063) 259,911     -
   Kaiser Peter Chief Development Officer   •       –      –    2025-08-25 4 S $12.04 $36,252 D/D (3,011) 204,093     -
  201 Records found
  1  2  3  4  5  6  7  8  9   
  Page 1 of 9
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2026 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us